Daxor Announces Placement of Three BVA-100 Blood Volume Analyzers
FOR: DAXOR CORP.
JUN 21, 2012 - 08:30 ET
NEW YORK, NY--(Marketwire - June 21, 2012) - Daxor Corporation (
Medicare has issued regulations which will penalize hospitals who readmit congestive heart failure patients in under 30 days. This regulation will be implemented in January 2013 and will provide a significant incentive for hospitals to optimize treatment of the congestive heart failure patients.
According to recent statistics 24.8% of congestive heart failure patients are readmitted for hospitalization within 30 days after being discharged. Treatment of congestive heart failure patients is the #1 expense for Medicare for patients over the age of 65.
Daxor Corporation manufactures and markets the BVA-100, which is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website at www.Daxor.com.
FOR FURTHER INFORMATION PLEASE CONTACT: